- Posted May 2, 2014 by
- Consumers Increasingly Becoming Concerned with Food Packaging Safety
- Seniors’ Narcotics Use Under Medicare is a Growing Concern – Report
- Growing Global Population Driving Force Behind Food Industry Mergers
- Pacific Shore Holdings, Inc. Aims to Become a Billion Company Within 5 Years in Green Scene Products Arena
- 52% More Restaurants to Offer Gluten-Free Dishes in 2014 – survey
Exclusive: BioCorRx Inches Closer to Acquisition of Trinity Rx Solutions
In an exclusive interview, BioCorRx COO Brady Grainier said the company is working on the acquisition, as well as develop other products and services in the healthcare industry.
“We are trying to complete the acquisition of Trinity Rx Solutions who owns the implant formula,” Grainier said referring to the US-based company.
Earlier in the year, the company filed a letter of understanding to acquire Trinity Rx Solutions and all of its formulas.
BioCorRx already has the exclusive rights to the naltrexone implant formula in the United States and the rest of the world, except Australia and New Zealand.
Upon acquisition, the company will be able to take control of production and supply of the naltrexone implant. It will also be able to utilize other Trinity Rx Solutions formulas that treat erectile dysfunction, smoking addiction and chronic pain.
Naltrexone is a popular medication used against opioid addiction. BioCorRx’s Start Fresh Program (http://www.startfreshprogram.com/) is hinged on naltrexone implants that allow easier recovery of people dependent on alcohol and prescription drugs.
“Most programs tend to focus on the psycho-social component of the person’s addiction alone. We feel that dealing with the physical addiction initially is very vital in increasing success rates. Without the intrusive physical cravings, patients are better able to absorb the teachings of the life coaches. Medicines like Naltrexone are very effective in virtually eliminating those cravings and we have one of the longest lasting implants in the world to help address the cravings,” Grainier said.
The procedure only lasts 20 to 30 minutes, under local anesthesia, and involves injection of the naltrexone implant in pellet form under the skin in the fatty tissue, in the lower abdominal area.
Grainier said their patients immediately feel the effects of the medication, two to three hours after the procedure. The effect, which reduces the cravings for addictive compounds, lasts for about six months.
“Once they are done with the procedure, they enter the life coaching phase of the program which includes 15 or more sessions usually over a 6 month period. In those sessions, the life coach helps the patient to develop tools that will enable them to recognize and deal with triggers that would normally cause them to use or drink. The coaching program is focused on moving forward and not looking back,” he said.
What makes the Start Fresh Program very effective is that it utilizes the medication to ensure a clean slate for the patients to work on. The comfort of not being able to relapse during the treatment helps them a lot. It is also more convenience to have the implant inserted than to take pills every day.
Unlike other anti-opioid addiction medication, naltrexone is not addictive, both in implant and drug form.
It is not surprising that the program’s success rate is at 85 percent for those who completed 15 or so sessions within six months.
BioCorRx (BICX, http://finance.yahoo.com/q?s=BICX) is a public company that has a market capitalization of around $20 million.